Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Regulation of Lipolysis and Lipolysis Proteins
NCT03866408Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Nov 2018
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of pioglitazone in obesity (4 arms), sponsored by Mayo Clinic. Primary endpoints: Adipocyte response to insulin - perilipin 1 and FSP27 relative to HSL and ATGL, Adipocyte response to insulin - adipocyte G0S2 relative to ATGL and 2 more. Started Nov 2018; status: recruiting.
02
Drugs
pioglitazone
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03866408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03866408.